Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Osteoporosis International

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-010-1501-1PMID 21184054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis

  2011cited by this paper
• The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.

  2010cited by this paper
• FRAX® assessment of osteoporotic fracture probability in Switzerland

  2010cited by this paper
• Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years

  2010cited by this paper
• Harmonization and standardization of thyroid function tests.

  2010cited by this paper
• Bone turnover markers and prediction of fracture: A prospective follow‐up study of 1040 elderly women for a mean of 9 years

  2010cited by this paper
• Report of the IFCC Working Group for Standardization of Thyroid Function Tests; part 1: thyroid-stimulating hormone.

  2010cited by this paper
• Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis

  2009cited by this paper
• Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study

  2009cited by this paper
• A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.

  2009cited by this paper
• Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.

  2009cited by this paper
• Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?

  2009cited by this paper
• Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

  2009cited by this paper
• Bone turnover markers in the management of postmenopausal osteoporosis.

  2009cited by this paper
• Traceability as a unique tool to improve standardization in laboratory medicine.

  2009cited by this paper
• Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study

  2009cited by this paper
• Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density

  2009cited by this paper
• Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States

  2009cited by this paper
• Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

  2009cited by this paper
• Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

  2009cited by this paper
• Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

  2009cited by this paper
• Bone turnover markers: understanding their value in clinical trials and clinical practice

  2009cited by this paper
• Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS)

  2009cited by this paper
• Traceability and standardization of immunoassays: a major challenge.

  2009cited by this paper
• Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover

  2009cited by this paper
• Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis

  2008cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cited by this paper
• A reference standard for the description of osteoporosis.

  2008cited by this paper
• Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial

  2008cited by this paper
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women

  2008cited by this paper
• Utility of Biochemical Markers of Bone Turnover and Bone Mineral Density in Management of Osteoporosis

  2008cited by this paper
• Establishing a reference range for bone turnover markers in young, healthy women.

  2008cited by this paper
• Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

  2008cited by this paper
• A revised clinician's guide to the prevention and treatment of osteoporosis.

  2008cited by this paper
• Determinants of Bone Turnover Markers in Healthy Premenopausal Women

  2008cited by this paper
• Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.

  2008cited by this paper
• Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis.

  2008cited by this paper
• Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.

  2008cited by this paper
• Standardization of troponin I measurements: an update

  2008cited by this paper
• Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)

  2008cited by this paper
• Risk Factors for Vertebral and Nonvertebral Fracture Over 10 Years: A Population‐Based Study in Women

  2007cited by this paper
• Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis

  2007cited by this paper
• Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis

  2007cited by this paper
• Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

  2007cited by this paper
• Traceability, reference systems and result comparability.

  2007cited by this paper
• Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis

  2007cited by this paper
• A cross-sectional study of bone turnover markers in healthy premenopausal women.

  2007cited by this paper
• The use of biochemical markers of bone turnover in osteoporosis.

  2007cited by this paper
• Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

  2007cited by this paper
• Discontinuation of antiresorptive therapies: a comparison between 1998-2001 and 2002-2004 among osteoporotic women.

  2007cited by this paper
• A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.

  2007cited by this paper
• Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025

  2007influential reference
• Hip and nonvertebral fracture prediction in nursing home patients: role of bone ultrasound and bone marker measurements.

  2007cited by this paper
• An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

  2006cited by this paper
• Toward standardization of cardiac troponin I measurements part II: assessing commutability of candidate reference materials and harmonization of cardiac troponin I assays.

  2006cited by this paper
• Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

  2006cited by this paper
• Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

  2006cited by this paper
• Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis

  2006cited by this paper
• Denosumab in postmenopausal women with low bone mineral density.

  2006cited by this paper
• Development of an algorithm for using PINP to monitor treatment of patients with teriparatide*

  2006cited by this paper
• Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae.

  2006cited by this paper
• Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

  2006cited by this paper
• One Year of Alendronate After One Year of Parathyroid Hormone (1–84) for Osteoporosis

  2006cited by this paper
• Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis

  2005cited by this paper
• Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters

  2005cited by this paper
• Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.

  2005cited by this paper
• Treatment of Postmenopausal Osteoporosis

  2005cited by this paper
• Requirements for DXA for the management of osteoporosis in Europe

  2005cited by this paper
• Changes in bone mass and bone turnover following tibial shaft fracture

  2005cited by this paper
• Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial

  2005cited by this paper
• Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study

  2005cited by this paper
• Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study

  2005cited by this paper
• Standardization of assays for human chorionic gonadotropin.

  2004cited by this paper
• Drugs Used to Treat Osteoporosis: The Critical Need for a Uniform Nomenclature Based on Their Action on Bone Remodeling

  2004cited by this paper
• Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.

  2004cited by this paper
• Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.

  2004cited by this paper
• Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

  2004cited by this paper
• The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

  2004cited by this paper
• IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.

  2004cited by this paper
• Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy.

  2004cited by this paper
• Bone Resorption and Osteoporotic Fractures in Elderly Men: The Dubbo Osteoporosis Epidemiology Study

  2004cited by this paper
• Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.

  2004cited by this paper
• Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial

  2004cited by this paper
• Treatment With Once‐Weekly Alendronate 70 mg Compared With Once‐Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double‐Blind Study

  2004cited by this paper
• The degree of mineralization is a determinant of bone strength: a study on human calcanei.

  2004cited by this paper
• Relative Contributions of Bone Density, Bone Turnover, and Clinical Risk Factors to Long‐Term Fracture Prediction

  2003cited by this paper
• Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women

  2003cited by this paper
• Biology of the basic multicellular unit and the pathophysiology of osteoporosis.

  2003cited by this paper
• Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk

  2003cited by this paper
• Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate

  2003cited by this paper
• Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate

  2003cited by this paper
• Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women.

  2003cited by this paper
• Biochemical Indices of Bone Turnover and the Assessment of Fracture Probability

  2002influential reference
• Treatment of postmenopausal osteoporosis.

  2002cited by this paper
• Mechanical Properties of Adult Vertebral Cancellous Bone: Correlation With Collagen Intermolecular Cross‐Links

  2002cited by this paper
• Type I Collagen Racemization and Isomerization and the Risk of Fracture in Postmenopausal Women: The OFELY Prospective Study

  2002cited by this paper
• A New Approach to the Development of Assessment Guidelines for Osteoporosis

  2002cited by this paper
• Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

  2002cited by this paper
• Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.

  2002cited by this paper

• TSH suppression attenuates the early efficacy of zoledronic acid in osteoporosis

  2026cites this paper
• Evaluation of salivary bone turnover markers and vitamin D as non-invasive, early predictive indicators of bone health in pre-, peri-, and post-menopausal women

  2026cites this paper
• Association of central adiposity and metabolic markers with osteopenia and osteoporosis in Chinese adults: a QCT-based cross-sectional study.

  2026cites this paper
• Profiling bone status indices reveals evidence of a low-turnover bone phenotype in type 2 diabetes: findings from the DiaFALL cohort.

  2026cites this paper
• A retrospective comparative study on the effects of denosumab combined with calcium and vitamin D versus calcium and vitamin D alone on bone remodeling markers in patients with osteoporotic fractures.

  2026cites this paper
• Comparison of indices of bone health among Indian adults with drug-resistant versus well-controlled epilepsy: A cross-sectional analytical pilot study

  2026cites this paper
• A biochemical perspective on bone-implant interface healing after cemented knee arthroplasty: role of serum calcium and ALP

  2026cites this paper
• Diagnostic value and role in promoting fracture healing of deregulated circulating miR-204 in patients with osteoporotic fractures

  2026cites this paper
• Protein compound macrophage migration inhibitory factor for diagnosing postmenopausal osteoporosis.

  2026cites this paper
• Does type 2 diabetes affect bone metabolism in patients after hip fracture? A case–control study

  2026cites this paper
• Bone turnover markers (β-CTX, PINP, ALP) in osteoporosis: correlation with bone loss and fracture risk stratification

  2026cites this paper
• Predicting Hip Osteoporosis with Routine Demographic and Biochemical Data: The Shao HipOsteoRisk Model

  2026cites this paper
• Personalized reference intervals based on biological variation for serum bone turnover markers in healthy older adults

  2026cites this paper
• Cxcr2 is Required for Osteoclast Regulation, Bone Structure, and Hematological Response During Bone (Re)modeling

  2026cites this paper
• Beyond DXA: Trabecular Bone Score, Quantitative Ultrasound and Bone Turnover Markers for Morphometric Vertebral Fracture Assessment in People Living with HIV

  2026cites this paper
• The chemicalome profiling of Zishen Yuzhen Pill in vivo and its promoting effect on osteogenic differentiation of MC3T3-E1 cells

  2025cites this paper
• Re-engineering bone: pathogenesis, diagnosis and emerging therapies for osteoporosis.

  2025cites this paper
• Proposed common reference intervals for reference bone turnover markers in osteoporosis.

  2025cites this paper
• Reference Intervals for 24-Hour Urinary Calcium Excretion and Its Association With Bone Metabolism: A Multicenter Study

  2025cites this paper
• The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axis.

  2025cites this paper
• Weighted Vest Use or Resistance Exercise to Offset Weight Loss–Associated Bone Loss in Older Adults

  2025cites this paper
• Novel Combination of Traditional Ayurvedic Herb Piper longum L. and Modern Stem Cell Therapy for the Reversal of Glucocorticoid-Induced Osteoporosis.

  2025cites this paper
• Super-high levels of serum intact-parathyroid hormone and bone turnover markers descended with recuperating allograft function and a short-term high-dose methylprednisolone during preoperative period of renal transplantation: a retrospective cohort study

  2025cites this paper
• Development and validation of a method for quantitation of CTx-1 for the assessment of biosimilarity of FKS518, a denosumab biosimilar.

  2025cites this paper
• Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women

  2025cites this paper
• Association between bone turnover markers and FRAX predicted fracture risk in Chinese adults: a cross-sectional study

  2025cites this paper
• The Role of Osteoporosis Agents in Enhancing Spinal Fusion

  2025cites this paper
• Bone metabolism in pathology: current practice and future directions.

  2025cites this paper
• Clinical Benefits of Denosumab vs Zoledronate in Postmenopausal Women Previously Treated with Alendronate: A Two-Year Retrospective Study

  2025cites this paper
• Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis: An Updated Systematic Review and Meta-analysis.

  2025cites this paper
• The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis

  2025cites this paper
• Anti-Mullerian Hormone and Collagen Type I C-telopeptide Predict Fast, Imminent Bone Loss in Early Perimenopause: SWAN.

  2025cites this paper
• Utilité clinique des marqueurs du remodelage osseux dans la prise en charge de l’ostéoporose, de l’ostéoporose associée aux maladies rénales chroniques et du diabète

  2025cites this paper
• Bone turnover markers are risk factors for endplate injuries during lumbar interbody fusion: a retrospective case-control study

  2025cites this paper
• Effects of Nigella sativa on Bone Turnover Markers in Postmenopausal Women: A Comprehensive Review

  2025cites this paper
• Muscle function mediates the association between vitamin D deficiency and hip fracture risk: a retrospective study in older adults

  2025cites this paper
• Protein intake, malnutrition, and its association with bone health after a hip fracture: A 3-month prospective study

  2025influential citation
• Neutrophil-to-albumin ratio: a novel predictor of osteoporosis in rheumatoid arthritis

  2025cites this paper
• Association between fibrinogen-to-albumin ratio and bone metabolism markers (β-CTX and P1NP) in Chinese individuals with osteoporotic fracture: a cross-sectional investigation

  2025cites this paper
• Severe Osteoporosis in Larsen Syndrome—A Case Report of Bone Morphology and A Novel Filamin B (FLNB) Variant

  2025cites this paper
• The Use of Bone Biomarkers, Imaging Tools, and Genetic Tests in the Diagnosis of Rare Bone Disorders

  2025cites this paper
• Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Calcium isotope ratio in patients with monogenic bone diseases: a prospective, cross-sectional, single-center pilot study

  2025cites this paper
• Efficacy and Safety of Percutaneous Kyphoplasty Combined With Zoledronic Acid for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis

  2025cites this paper
• Establishment of Biological Reference Intervals for Type I Collagen Cross-Linked N-Telopeptide (NTx) in Adults in the Qingdao Region

  2025cites this paper
• Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval

  2025cites this paper
• Age-stratified association between serum uric acid and lumbar bone mineral density in elderly Chinese women with vertebral compression fractures: a cross-sectional analysis

  2025cites this paper
• Medication Effect Upon Orthodontic Tooth Movement

  2025cites this paper
• Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study.

  2025cites this paper
• Advances in the application of bone turnover markers for pediatric growth and developmental disorders: a review

  2025cites this paper
• OSTEOPOROSIS IN MEN – A CONTEMPORARY PERSPECTIVE ON DIAGNOSIS, TREATMENT AND FRACTURE PREVENTION STRATEGIES

  2025cites this paper
• Unveiling the role of post-translational modifications in bone metabolism: implications for osteoporosis

  2025cites this paper
• RELATIONSHIP BETWEEN HOMOCYSTEINE LEVELS AND BONE QUALITY IN HEALTHY ADULTS - A SYSTEMATIC REVIEW AND META-ANALYSIS.

  2025cites this paper
• The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference

  2025cites this paper
• Are there associations between bone turnover and hip geometry in the general population?

  2025cites this paper
• Monitoring denosumab therapy using the calcium isotope marker (CIM) technology.

  2025cites this paper
• Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis

  2025cites this paper
• Crosstalk between kidney and bones: New perspective for modulating osteoporosis.

  2025cites this paper
• Osteoporotic vertebral fractures and subsequent fractures: risk factors from a retrospective observational study of patients with osteoporosis

  2025cites this paper
• Effect of vitamin B1 supplementation on bone turnover markers in adults: an exploratory single-arm pilot study

  2025cites this paper
• Prevention of osteoporosis in ovariectomized mice with yak caseinate calcium.

  2025cites this paper
• Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw.

  2025cites this paper
• The Importance of Bone Health in Complex Spine Surgery

  2025cites this paper
• More Than Just Bone Pain: A Case of Paget’s Disease, Seropositive Rheumatoid Arthritis, and Metabolic Dysfunction-Associated Steatohepatitis (MASH) in a Patient With Elevated Alkaline Phosphatase (ALP)

  2025cites this paper
• Bone turnover markers and mineral density in type 1 diabetes - A cross-sectional study: DIAFALL.

  2025cites this paper
• Predictive Value of Bone Metabolism Marker PINP in the Risk of Diabetic Retinopathy: A Cross-Sectional Study

  2025cites this paper
• Oral Administration of Hydrolyzed Egg Yolk Peptides With Low Molecular Weight Increased Bone Density by Regulating Bone Metabolism and Immune Responses

  2025cites this paper
• The Effects of Ingesting a Single Bolus of Hydrolyzed Collagen versus Free Amino Acids on Muscle Connective Protein Synthesis Rates

  2025cites this paper
• Emerging Diagnostic Approaches for Musculoskeletal Disorders: Advances in Imaging, Biomarkers, and Clinical Assessment

  2025cites this paper
• Comparison of bone mineral density changes between denosumab and bisphosphonates in tenofovir-exposed chronic hepatitis B patients with osteoporosis

  2025cites this paper
• Functional Evaluation of Arabinogalactan Isolated from Hyuganatsu Orange

  2025cites this paper
• Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective.

  2025cites this paper
• Impacts of aerobic exercise and whole-body vibration interventions on myokines and neurocognitive performance in postmenopausal women.

  2025cites this paper
• Association of Energy, Macronutrients, and Fiber Intakes with Bone Health in Adolescent Athletes

  2025cites this paper
• The Association of Bone-related Biomarkers With Incident Hip Fracture: A Nested Case-control Study

  2025cites this paper
• Efficacy and safety of denosumab biosimilar CMAB807 versus Prolia® in Chinese postmenopausal women with osteoporosis

  2025cites this paper
• Novel therapies in osteoporosis - Clinical update - 2025.

  2025cites this paper
• Risk prediction of osteoporotic vertebral compression fractures in postmenopausal osteoporotic women by machine learning modelling

  2025cites this paper
• Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on bone mineral density

  2025cites this paper
• Influence of vitamin D status on the variability of collagen I C-telopeptide in pre- and post-menopausal healthy women

  2025cites this paper
• Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study

  2025cites this paper
• Reduction of subchondral bone marrow lesions concurrent with early recovery of trabecular bone mineral density in knee osteoarthritis following RANKL inhibitor administration for the treatment of osteoporosis: Implying human osteoporotic osteoarthritis?

  2025cites this paper
• Activity of Selected Bone Formation and Angiogenesis Markers During the Treatment of Limb Length Discrepancy in Children Using Distraction Osteogenesis with the Circular Hexapod External Fixator

  2025cites this paper
• Heavy resistance training provides short-term benefits on bone formation in well-functioning older adults.

  2025cites this paper
• Chronic Kidney Disease‐Mineral Bone Disorder (CKD‐MBD) in Pediatric Kidney Transplant Recipients

  2025cites this paper
• Association between bone turnover markers, bone mineral density, and serum osteoglycine in middle-aged men with Type 2 Diabetes mellitus

  2024cites this paper
• Efficacy of lumbar and abdominal muscle rehabilitation training on degree of osteoporosis, pain and anxiety in elderly patients with osteoporotic vertebral compression fracture after PKP and compliance analysis

  2024cites this paper
• Risk and prevalence of Relative Energy Deficiency in Sport (REDs) among professional female football players

  2024influential citation
• Insight into the potential of bone turnover biomarkers: integration in the management of osteoporosis and chronic kidney disease-associated osteoporosis

  2024cites this paper
• Surrogate markers in assessment of bisphosphonate effectiveness in osteoporosis treatment (bone mineral density, bone turnover markers)

  2024cites this paper
• A comprehensive approach for osteoporosis detection through chest CT analysis and bone turnover markers: harnessing radiomics and deep learning techniques

  2024cites this paper
• Changes in the concentration of bone turnover markers in men after maximum intensity exercise

  2024cites this paper
• Hydrolyzed egg yolk powder promotes bone growth and development in rats: A multidimensional mechanistic study

  2024cites this paper
• Changes in serum bone turnover markers and bone mineral density Z-score in children with osteogenesis imperfecta after zoledronic acid treatment

  2024cites this paper
• Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar

  2024cites this paper
• Comparison of the pleiotropic effect of atorvastatin and rosuvastatin on postmenopausal changes in bone turnover: A randomized comparative study

  2024cites this paper
• Dairy consumption, bone turnover biomarkers, and osteo sono assessment index in Japanese adults: A cross-sectional analysis of data from the Iwaki Health Promotion Project

  2024cites this paper
• Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment

  2024cites this paper
• PoCOsteo: generic novel platform for bone turnover marker measurement & monitoring.

  2024cites this paper
• Space research to explore novel biochemical insights on Earth.

  2024cites this paper